Kelly CRISPR & Gene Editing Technology ETF Price & Performance (XDNA)

CRISPR Therapeutics AG is attracting bullish analyst sentiment as new regulatory developments in the U.S. could drive reimbursement and approval for its gene therapy Casgevy. Wall Street sees potential for the stock to nearly double within a year, though long-term uncertainties persist for the pioneering biotech firm.12

Recent filings show the Kelly CRISPR & Gene Editing ETF increased allocations to CRISPR Therapeutics, Beam Therapeutics, and Prime Medicine, while trimming positions in Intellia and Thermo Fisher. These shifts reflect changing market valuations and strategic bets on gene editing’s evolving landscape.34

The Kelly CRISPR & Gene Editing Technology ETF continues to focus on sector leaders, with CRISPR Therapeutics, Beam Therapeutics, Thermo Fisher, Intellia, and Prime Medicine comprising its largest positions. The fund’s recent performance and asset allocation underscore ongoing confidence in the growth prospects of gene editing technologies.56